Kim Chi, MD, FRCPC, discusses the rationale and design of the phase 3 KLK2-comPAS trial evaluating pasritamig alone and in combination with JNJ-9401 in patients with mCRPC.
Kim Nguyen Chi, MD, FRCPC
Advertisement
Chi is the chief medical officer of BC Canada and a professor of medicine at the University of British Columbia in Canada.
Articles by Kim Nguyen Chi, MD, FRCPC
Kim Chi, MD, highlights findings from a pre-planned analysis of the PLUDO trial examining the impact of crossover on survival outcomes between 177Lu-PSMA-617 vs docetaxel in mCRPC.
The phase 3 AMPLITUDE trial evaluated the safety and efficacy of adding niraparib to abiraterone acetate plus prednisone in patients with mHSPC.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Urology Times
1
FDA grants De Novo authorization to Virtuoso Robotic System for bladder tumor resection
2
Pasritamig combination yields 73% PSA response rate in phase 1 mCRPC study
3
Q&A: Suzanne B. Merrill, MD, FACS, on perioperative therapy in MIBC
4
SureCore needle: Interim data show longer, less fragmented cores
5